EX-99.1 4 dp48071_ex9901.htm EXHIBIT 99.1
Exhibit 99.1
 
 
 
Non GAAP Financial Measures

Shire reports certain financial measures on a “Non GAAP” basis. These Non GAAP measures are not prepared in accordance with US GAAP.

Non GAAP measures exclude the effect of certain cash and non-cash items that Shire's management believes are not related to the core performance of Shire’s business, and are used by Shire’s management to make operating decisions because they facilitate internal comparisons of Shire’s performance to historical results and to competitors’ results. Shire’s Remuneration Committee uses certain key Non GAAP measures when assessing the performance and compensation of employees, including Shire’s executive director.

The Rule 2.7 Announcement released on 18 July 2014, includes the following Non GAAP financial measures:

 
·
Non GAAP EBITDA margin as percentage of product sales;
 
·
Non GAAP EBITDA; and
 
·
Last Twelve Months Non GAAP EBITDA.

Shire’s management believe that these Non GAAP financial measures provide investors with a means of evaluating, and an understanding of how Shire’s management evaluates, Shire’s performance and results on a comparable basis that is not otherwise apparent on a US GAAP basis, since many non-recurring, infrequent or non-cash items that Shire’s management believe are not indicative of the core performance of the business may not be excluded when preparing financial measures under US GAAP.

These Non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.

Where applicable the following items, including their tax effect, have been excluded when calculating the relevant Non GAAP financial measures:

Amortization and asset impairments:
·
Intangible asset amortization and impairment charges; and
·
Other than temporary impairment of investments.

Acquisitions and integration activities:
·
Up-front payments and milestones in respect of in-licensed and acquired products;
·
Costs associated with acquisitions, including transaction costs, fair value adjustments on contingent consideration and acquired inventory;
·
Costs associated with the integration of companies; and
·
Noncontrolling interests in consolidated variable interest entities.

Divestments, reorganizations and discontinued operations:
·
Gains and losses on the sale of non-core assets;
·
Costs associated with restructuring and reorganization activities;
·
Termination costs; and
·
Income/(losses) from discontinued operations.

Legal and litigation costs:
·
Net legal costs related to the settlement of litigation, government investigations and other disputes (excluding internal legal team costs).

Depreciation, which is included in Cost of product sales, R&D and SG&A costs in our US GAAP results, has been separately disclosed for the presentation of Non GAAP earnings.

Cash generation represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, tax and interest payments.

Free cash flow represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, but including capital expenditure in the ordinary course of business.

A reconciliation of Shire’s Non GAAP cost of product sales, Non GAAP R&D, and Non GAAP SG&A for Q1 2013 and Q1 2014, to the most directly comparable measure under US GAAP, can be found within Shire’s Q1 2014 earnings release, in the Investors section of Shire’s website:

http://www.shire.com/shireplc/en/investors/presentations
 
 
 

 

 
Reconciliations of (a) Non GAAP EBITDA margin as percentage of product sales, (b) Non GAAP EBITDA, and (c) Last Twelve Months Non GAAP EBITDA to the most directly comparable measures under US GAAP are included below.

 
(a)
Non GAAP EBITDA margin as percentage of product sales (Q1 2014 & Q1 2013)

 
The following table reconciles US GAAP Net Income to Non GAAP EBITDA for Q1 2014 and Q1 2013:
 
   
For the Quarter Ended March 31,
 
   
(US$ in millions)
 
      Q1 2014       Q1 2013  
US GAAP  Net income
    230.4       64.8  
 
(Deduct) / add back:
               
Loss from discontinued operations, net of tax
    22.7       216.2  
Equity in losses/(earnings) of equity method investees, net of taxes
    0.6       (0.4 )
Income taxes
    50.6       71.4  
Other (income)/expense, net
    (4.7 )     1.0  
Interest expense
    7.8       9.2  
Interest income
    (0.5 )     (0.7 )
 
US GAAP Operating income from continuing operations
    306.9       361.5  
 
Amortization
    57.8       36.1  
Depreciation
    36.8       27.8  
Asset impairments
    166.0       7.1  
Integration and acquisition costs
    45.4       4.1  
Divestments, reorganizations and discontinued operations
    13.0       11.0  
Legal and litigation costs
    1.7       1.6  
 
Non GAAP EBITDA
    627.6       449.2  
 
Depreciation
    (36.8 )     (27.8 )
 
Non GAAP Operating income from continuing operations
    590.8       421.4  
Non GAAP EBITDA* as percentage of product sales
    45 %     37 %
* Excluding royalties and other revenues
               
 
 
(b)
Non GAAP EBITDA (2008-2013)

The following table reconciles US GAAP Net Income to Non GAAP EBITDA:
 
    For the Year Ended December 31,  
    (US$ in millions)  
   
2013
   
2012
   
2011
   
2010
   
2009
   
2008
 
US GAAP Net income     665.1       745.4       865.0       588.0       491.6       156.0  
                                                 
(Deduct) / add back:
                                               
Net loss attributable to noncontrolling interest in subsidiaries
    -       -       -       -       (0.2 )     (3.6 )
Loss from discontinued operations net of tax
    754.5       60.3       17.7       -       12.4       17.6  
Equity in (earnings)/losses of equity method investees, net of taxes
    (3.9 )     (1.0 )     (2.5 )     (1.4 )     0.7       (2.4 )
Income taxes
    277.9       203.1       236.9       182.7       138.5       98.0  
Other expense/(income), net
    3.9       2.2       (18.5 )     (7.9 )     (60.7 )     32.9  
Interest expense
    38.1       38.2       39.1       35.1       39.8       139.0  
Interest income
    (2.1 )     (3.0 )     (1.9 )     (2.4 )     (1.9 )     (25.5 )
 
US GAAP Operating income from continuing operations
    1,733.5       1,045.2       1,135.8       794.1       620.2       412.0  
 
Amortization
    152.0       153.6       145.0       133.5       136.9       126.2  
Depreciation
    127.6       109.0       119.5       93.5       93.0       77.2  
Asset impairments
    27.0       197.9       16.0       42.7       -       97.1  
Integration and acquisition costs
    (134.1 )     36.5       0.1       53.0       51.0       273.4  
Divestments, reorganizations and discontinued operations
    72.3       (18.1 )     41.6       48.2       81.3       49.4  
Legal and litigation costs
    9.0       94.1       -       -       -       -  
 
Non GAAP EBITDA
    1,987.3       1,618.2       1,458.0       1,165.0       982.4       1,035.3  
 
Depreciation
    (127.6 )     (109.0 )     (119.5 )     (93.5 )     (93.0 )     (77.2 )
 
Non GAAP Operating income from continuing operations
    1,859.7       1,509.2       1,338.5       1,071.5       889.4       958.1  

 
 

 
 
 
 
(c)
Last Twelve Months Non GAAP EBITDA (Q1 2014)

 
The following table reconciles Last Twelve Months US GAAP Net Income to Last Twelve Months Non GAAP EBITDA for Q1 2014:
 
   
Twelve Months ended March 31, 2014
 
       
   
(US$ in millions)
 
       
US GAAP  Net income
    830.7  
 
(Deduct) / add back:
       
Loss from discontinued operations, net of tax
    561.0  
Equity in earnings of equity method investees, net of taxes
    (2.9 )
Income taxes
    257.1  
Other income, net
    (1.8 )
Interest expense
    36.7  
Interest income
    (1.9 )
 
US GAAP Operating income from continuing operations
    1,678.9  
 
Amortization
    173.7  
Depreciation
    136.6  
Asset impairments
    185.9  
Integration and acquisition costs
    (92.8 )
Divestments, reorganizations and discontinued operations
    74.3  
Legal and litigation costs
    9.1  
 
Non GAAP EBITDA
    2,165.7  
 
Depreciation
    (136.6 )
 
Non GAAP Operating income from continuing operations
    2,029.1